Current studies with docetaxel in hormone-refractory prostate cancer: selected presentations from the 27th European Society for Medical Oncology Congress, 2002.
作者信息
DeGrendele Heather
出版信息
Clin Prostate Cancer. 2003 Mar;1(4):212-4. doi: 10.1016/s1540-0352(11)70004-x.
Abstract
摘要
相似文献
1
Current studies with docetaxel in hormone-refractory prostate cancer: selected presentations from the 27th European Society for Medical Oncology Congress, 2002.
Clin Prostate Cancer. 2003 Mar;1(4):212-4. doi: 10.1016/s1540-0352(11)70004-x.
2
[Prostate cancer: future strategies for chemotherapy management].
Ann Urol (Paris). 2007 Oct;41 Suppl 3:S77-9. doi: 10.1016/s0003-4401(07)80514-6.
3
The current role of chemotherapy in metastatic hormone-refractory prostate cancer.
Urology. 2005 May;65(5 Suppl):3-7; discussion 7-8. doi: 10.1016/j.urology.2005.03.053.
4
Controversies in chemotherapy of prostate cancer.
Front Radiat Ther Oncol. 2002;36:72-80. doi: 10.1159/000061331.
5
Current chemotherapeutic approaches for androgen-independent prostate cancer.
Curr Opin Investig Drugs. 2006 Jun;7(6):529-33.
6
[Therapy of hormone refractory prostate cancer: new standards, new trends].
Aktuelle Urol. 2005 Aug;36(4):342-8. doi: 10.1055/s-2004-830209.
7
Castration refractory prostate cancer: cinderella finally comes to the ball.
Onkologie. 2010;33(12):655-6. doi: 10.1159/000322635. Epub 2010 Nov 29.
8
Epothilones and the next generation of phase III trials for prostate cancer.
BJU Int. 2005 Aug;96(3):296-302. doi: 10.1111/j.1464-410X.2005.05618.x.
9
Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer.
Urology. 2003 Apr;61(4):774-80. doi: 10.1016/s0090-4295(02)02519-0.
10
[Hormone-refractory prostate cancer].
Ann Urol (Paris). 2007 Apr;41(2):47-55. doi: 10.1016/j.anuro.2007.02.003.
Zotero 插件